Key result
Midazolam administration decreased left ventricular contractility and reduced mean arterial pressure without changing cardiac index.
Why the study?
Does midazolam affect left ventricular pump performance and contractility in patients undergoing coronary artery bypass grafting?
Does midazolam affect left ventricular pump performance and contractility in patients undergoing coronary artery bypass grafting?
Midazolam administration in patients undergoing CABG decreases LV contractility without affecting overall cardiac pump performance, even in those with depressed ejection fraction.
Answers are grounded in this paper and cite their sources.
Midazolam may reduce LV contractility and MAP in CABG patients without altering cardiac index; leaves open relevance for those with low EF.
Forty patients undergoing coronary artery bypass grafting were studied, of whom 24 had depressed global left ventricular (LV) function at preoperative catheterization, to evaluate the effects of midazolam on LV pump performance and contractility. Transesophageal echocardiography and simultaneous hemodynamic measurements were used to assess LV preload, afterload, and systolic performance during inhalation of 100% O2 and after 0.1 mg/kg of midazolam. Systolic function indices were expressed as a percent of the predicted value for observed end-systolic stress to estimate LV contractility. In the entire study population, midazolam did not affect cardiac index. Heart rate and mean arterial pressure were reduced (63 +/- 13 to 59 +/- 12 bm; P < 0.0006 and 89 +/- 15 to 76 +/- 16 mm Hg; P < 0.0001) as were pulmonary capillary wedge pressure, central venous pressure, and systemic and pulmonary vascular resistance. Afterload, as measured by end-systolic stress, was reduced (55 +/- 33 to 48 +/- 26 kdyne/cm2; P = 0.007) with no change in fractional shortening or percent area change. As a result, systolic function decreased in relation to observed end-systolic stress, providing evidence of reduced LV contractility. Thus, midazolam administration (0.1 mg/kg) caused no change in cardiac pump performance but decreased LV contractility in the entire population. Myocardial contractility was lower at baseline and after the administration of midazolam in the depressed ejection fraction group, but the decrease in contractility was not exaggerated in the depressed ejection fraction group.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Messina et al. (1995) studied Coronary artery disease (n=40). Midazolam vs. Baseline was evaluated on Left ventricular pump performance and contractility. Midazolam administration decreased left ventricular contractility and reduced mean arterial pressure without changing cardiac index.
Synapse has enriched 10 related papers. Consider them for comparative context: